Adenosine A2A receptor antagonism increases nNOS-immunoreactive neurons in the striatum of Huntington transgenic mice

Experimental Neurology

Volumn 213, Issue 1, 2008, Pages 163-170

  Cipriani, S ^a   Bizzoco, E ^a   Gianfriddo, M ^b   Melani, A ^a,c   Vannucchi, M G ^a   Pedata, F ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Siena Biotech SpA   (Italy)

^c IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

Author keywords

AdenosineA2A receptors; Glial cellsBehaviorImmunohistochemistry; Huntington's disease; nNOS; R6 2 mice

Indexed keywords

5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR ANTAGONIST; NEURONAL NITRIC OXIDE SYNTHASE; ADENOSINE; NEUROPROTECTIVE AGENT; NITRIC OXIDE; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BRAIN CORTEX; BRAIN NERVE CELL; BRAIN PROTECTION; CELL ACTIVATION; CONTROLLED STUDY; CORPUS STRIATUM; GLIA CELL; HUNTINGTON CHOREA; LONG TERM CARE; MALE; MOTOR PERFORMANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; ROTAROD TEST; TRANSGENIC MOUSE; WALKING; ANIMAL; BIOSYNTHESIS; CELL PROTECTION; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ACTIVATION; INTERNEURON; METABOLISM; NITRERGIC NERVE; PATHOPHYSIOLOGY; PHYSIOLOGY; UPREGULATION;

ADENOSINE; ANIMALS; CORPUS STRIATUM; CYTOPROTECTION; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; HUNTINGTON DISEASE; INTERNEURONS; MALE; MICE; MICE, TRANSGENIC; NEUROPROTECTIVE AGENTS; NITRERGIC NEURONS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE I; PYRIMIDINES; RECEPTOR, ADENOSINE A2A; TRIAZOLES; UP-REGULATION;

EID: 49349092164     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2008.05.015     Document Type: Article

References (75)

1. Albin R.L., Reiner A., Anderson K.D., Penney J.B., and Young A.B. Striatal and nigral neuron subpopulations in rigid Huntington's disease: implications for the functional anatomy of chorea and rigidity-akinesia. Ann. Neurol. 27 (1990) 357-365
2. Beal M.F. Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci. 23 (2000) 298-304
3. Beal M.F., Kowall N.W., Swartz K.J., Ferrante R.J., and Martin J.B. Differential sparing of somatostatin-neuropeptide Y and cholinergic neurons following striatal excitotoxin lesions. Synapse 3 (1989) 38-47
4. Blum D., Hourez R., Galas M.C., Popoli P., and Schiffmann S.N. Adenosine receptors and Huntington's disease: implications for pathogenesis and therapeutics. Lancet Neurol. 2 (2003) 366-374
5. Bockelmann R., Wolf G., Ransmayr G., and Riederer P. NADPH-diaphorase/nitric oxide synthase containing neurons in normal and Parkinson's disease putamen. J. Neural. Transm. Park Dis. Dement. Sect. 7 (1994) 115-121
6. Cha J.H., Frey A.S., Alsdorf S.A., Kerner J.A., Kosinski C.M., Mangiarini L., Penney Jr. J.B., Davies S.W., Bates G.P., and Young A.B. Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. Philos. Trans. R. Soc. Lond B Biol. Sci. 354 (1999) 981-989
7. Chan E.Y., Luthi-Carter R., Strand A., Solano S.M., Hanson S.A., DeJohn M.M., Kooperberg C., Chase K.O., DiFiglia M., Young A.B., Leavitt B.R., Cha J.H., Aronin N., Hayden M.R., and Olson J.M. Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease. Hum. Mol. Genet. 11 (2002) 1939-1951
8. Chen S., and Aston-Jones G. Cerebellar injury induces NADPH diaphorase in Purkinje and inferior olivary neurons in the rat. Exp. Neurol. 126 (1994) 270-276
9. Chiang M.C., Lee Y.C., Huang C.L., and Chern Y. cAMP-response element-binding protein contributes to suppression of the A2A adenosine receptor promoter by mutant Huntingtin with expanded polyglutamine residues. J. Biol. Chem 280 (2005) 14331-14340
10. Chou S.Y., Lee Y.C., Chen H.M., Chiang M.C., Lai H.L., Chang H.H., Wu Y.C., Sun C.N., Chien C.L., Lin Y.S., Wang S.C., Tung Y.Y., Chang C., and Chern Y. CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model. J. Neurochem. 93 (2005) 310-320
11. Cicchetti F., Gould P.V., and Parent A. Sparing of striatal neurons coexpressing calretinin and substance P (NK1) receptor in Huntington's disease. Brain Res. 730 (1996) 232-237
12. Dawbarn D., De Quidt M.E., and Emson P.C. Survival of basal ganglia neuropeptide Y-somatostatin neurones in Huntington's disease. Brain Res. 340 (1985) 251-260
13. Dawson V.L., Brahmbhatt H.P., Mong J.A., and Dawson T.M. Expression of inducible nitric oxide synthase causes delayed neurotoxicity in primary mixed neuronal-glial cortical cultures. Neuropharmacology 33 (1994) 1425-1430
14. Deckel A.W., Gordinier A., Nuttal D., Tang V., Kuwada C., Freitas R., and Gary K.A. Reduced activity and protein expression of NOS in R6/2 HD transgenic mice: effects of L-NAME on symptom progression. Brain Res. 919 (2001) 70-81
15. Deckel A.W., Tang V., Nuttal D., Gary K., and Elder R. Altered neuronal nitric oxide synthase expression contributes to disease progression in Huntington's disease transgenic mice. Brain Res. 939 (2002) 76-86
16. Domenici M.R., Scattoni M.L., Martire A., Lastoria G., Potenza R.L., Borioni A., Venerosi A., Calamandrei G., and Popoli P. Behavioral and electrophysiological effects of the adenosine A(2A) receptor antagonist SCH 58261 in R6/2 Huntington's disease mice. Neurobiol. Dis. 28 (2007) 197-205
17. El Yacoubi M., Ledent C., Parmentier M., Ongini E., Costentin J., and Vaugeois J.M. In vivo labelling of the adenosine A2A receptor in mouse brain using the selective antagonist [3H]SCH 58261. Eur. J. Neurosci. 14 (2001) 1567-1570
18. Ferrante R.J., Kowall N.W., Beal M.F., Richardson Jr. E.P., Bird E.D., and Martin J.B. Selective sparing of a class of striatal neurons in Huntington's disease. Science 230 (1985) 561-563
19. Ferre S., von Euler G., Johansson B., Fredholm B.B., and Fuxe K. Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes. Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 7238-7241
20. Fink J.S., Kalda A., Ryu H., Stack E.C., Schwarzschild M.A., Chen J.F., and Ferrante R.J. Genetic and pharmacological inactivation of the adenosine A2A receptor attenuates 3-nitropropionic acid-induced striatal damage. J. Neurochem. 88 (2004) 538-544
21. Fusco F.R., Zuccato C., Tartari M., Martorana A., De March Z., Giampa C., Cattaneo E., and Bernardi G. Co-localization of brain-derived neurotrophic factor (BDNF) and wild-type huntingtin in normal and quinolinic acid-lesioned rat brain. Eur. J Neurosci. 18 (2003) 1093-1102
22. Ghelardini C., Galeotti N., Pecori Vettori A., Capaccioli S., Quattrone A., and Bartolini A. Effect of K+ channel modulation on mouse feeding behaviour. Eur. J. Pharmacol. 329 (1997) 1-8
23. Gianfriddo M., Melani A., Turchi D., Giovannini M.G., and Pedata F. Adenosine and glutamate extracellular concentrations and mitogen-activated protein kinases in the striatum of Huntington transgenic mice. Selective antagonism of adenosine A2A receptors reduces transmitter outflow. Neurobiol. Dis. 17 (2004) 77-88
24. Glass M., Dragunow M., and Faull R.L. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 97 (2000) 505-519
25. Grunewald T., and Beal M.F. Bioenergetics in Huntington's disease. Ann. N. Y. Acad. Sci. 893 (1999) 203-213
26. Harrington K.M., and Kowall N.W. Parvalbumin immunoreactive neurons resist degeneration in Huntington's disease striatum. J. Neuropathol. Exp. Neurol. 50 (1991) 309
27. Heneka M.T., Loschmann P.A., Gleichmann M., Weller M., Schulz J.B., Wullner U., and Klockgether T. Induction of nitric oxide synthase and nitric oxide-mediated apoptosis in neuronal PC12 cells after stimulation with tumor necrosis factor-alpha/lipopolysaccharide. J Neurochem. 71 (1998) 88-94
28. Hettinger B.D., Lee A., Linden J., and Rosin D.L. Ultrastructural localization of adenosine A2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum. J. Comp Neurol. 431 (2001) 331-346
29. Hirsch E.C., Graybiel A.M., Hersh L.B., Duyckaerts C., and Agid Y. Striosomes and extrastriosomal matrix contain different amounts of immunoreactive choline acetyltransferase in the human striatum. Neurosci. Lett. 96 (1989) 145-150
30. Hortobagyi T., Gorlach C., Benyo Z., Lacza Z., Hortobagyi S., Wahl M., and Harkany T. Inhibition of neuronal nitric oxide synthase-mediated activation of poly(ADP-ribose) polymerase in traumatic brain injury: neuroprotection by 3-aminobenzamide. Neuroscience 121 (2003) 983-990
31. Iadecola C. Bright and dark sides of nitric oxide in ischemic brain injury. Trends Neurosci. 20 (1997) 132-139
32. Iadecola C., Xu X., Zhang F., el Fakahany E.E., and Ross M.E. Marked induction of calcium-independent nitric oxide synthase activity after focal cerebral ischemia. J Cereb. Blood Flow Metab 15 (1995) 52-59
33. Iadecola C., Zhang F., Casey R., Nagayama M., and Ross M.E. Delayed reduction of ischemic brain injury and neurological deficits in mice lacking the inducible nitric oxide synthase gene. J Neurosci. 17 (1997) 9157-9164
34. Jarvis M.F., and Williams M. Direct autoradiographic localization of adenosine A2 receptors in the rat brain using the A2-selective agonist, [3H]CGS 21680. Eur. J. Pharmacol. 168 (1989) 243-246
35. Latini S., and Pedata F. Adenosine in the central nervous system: release mechanisms and extracellular concentrations. J. Neurochem. 79 (2001) 463-484
36. Lipsky R.H., and Marini A.M. Brain-derived neurotrophic factor in neuronal survival and behavior-related plasticity. Ann. N. Y. Acad. Sci. 1122 (2007) 130-143
37. Lynch G., Kramar E.A., Rex C.S., Jia Y., Chappas D., Gall C.M., and Simmons D.A. Brain-derived neurotrophic factor restores synaptic plasticity in a knock-in mouse model of Huntington's disease. J Neurosci. 27 (2007) 4424-4434
38. Ma L., Morton A.J., and Nicholson L.F. Microglia density decreases with age in a mouse model of Huntington's disease. Glia 43 (2003) 274-280
39. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., and Bates G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87 (1996) 493-506
40. Melani A., Pantoni L., Bordoni F., Gianfriddo M., Bianchi L., Vannucchi M.G., Bertorelli R., Monopoli A., and Pedata F. The selective A2A receptor antagonist SCH 58261 reduces striatal transmitter outflow, turning behavior and ischemic brain damage induced by permanent focal ischemia in the rat. Brain Res. 959 (2003) 243-250
41. Melani, A., Gianfriddo, M., Vannucchi, M.G., Cipriani, S., Baraldi, P.G., Giovannini, M.G., Pedata, F., 2006. The selective A2A receptor antagonist SCH 58261 protects from neurological deficit, brain damage and activation of p38 MAPK in rat focal cerebral ischemia. Brain Res. 1073-1074, 470-480.
42. Monopoli A., Casati C., Lozza G., Forlani A., and Ongini E. Cardiovascular pharmacology of the A2A adenosine receptor antagonist, SCH 58261, in the rat. J. Pharmacol. Exp. Ther. 285 (1998) 9-15
43. Nogawa S., Forster C., Zhang F., Nagayama M., Ross M.E., and Iadecola C. Interaction between inducible nitric oxide synthase and cyclooxygenase-2 after cerebral ischemia. Proc. Natl. Acad. Sci. U. S. A 95 (1998) 10966-10971
44. Norris P.J., Waldvogel H.J., Faull R.L., Love D.R., and Emson P.C. Decreased neuronal nitric oxide synthase messenger RNA and somatostatin messenger RNA in the striatum of Huntington's disease. Neuroscience 72 (1996) 1037-1047
45. Pedata F., Gianfriddo M., Turchi D., and Melani A. The protective effect of adenosine A2A receptor antagonism in cerebral ischemia. Neurol. Res. 27 (2005) 169-174
46. Perez-Severiano F., Escalante B., Vergara P., Rios C., and Segovia J. Age-dependent changes in nitric oxide synthase activity and protein expression in striata of mice transgenic for the Huntington's disease mutation. Brain Res. 951 (2002) 36-42
47. Pintor A., Galluzzo M., Grieco R., Pèzzola A., Reggio R., and Popoli P. Adenosine A2A receptor antagonists prevent the increase in striatal glutamate levels induced by glutamate uptake inhibitors. J. Neurochem. 89 (2004) 152-156
48. Popoli P., Blum D., Martire A., Ledent C., Ceruti S., and Abbracchio M.P. Functions, dysfunctions and possible therapeutic relevance of adenosine A2A receptors in Huntington's disease. Prog. Neurobiol. 81 (2007) 331-348
49. Popoli P., Blum D., Pintor A., Tebano M.T., Frank C., Gianfriddo M., Domenici M.R., Schiffmann S.N., and Pedata F. The controversial role of adenosine A2A receptor antagonists as neuroprotective agents. Curr. Med. Chem - Central Nervous System Agents 4 (2004) 35-45
50. Popoli P., Pintor A., Domenici M.R., Frank C., Tebano M.T., Pezzola A., Scarchilli L., Quarta D., Reggio R., Malchiodi-Albedi F., Falchi M., and Massotti M. Blockade of striatal adenosine A2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum. J Neurosci. 22 (2002) 1967-1975
51. Reiner A., Albin R.L., Anderson K.D., D'Amato C.J., Penney J.B., and Young A.B. Differential loss of striatal projection neurons in Huntington disease. Proc. Natl. Acad. Sci. U. S. A 85 (1988) 5733-5737
52. Rivlin A.S., and Tator C.H. Objective clinical assessment of motor function after experimental spinal cord injury in the rat. J.Neurosurg. 47 (1977) 577-581
53. Sapp E., Kegel K.B., Aronin N., Hashikawa T., Uchiyama Y., Tohyama K., Bhide P.G., Vonsattel J.P., and DiFiglia M. Early and progressive accumulation of reactive microglia in the Huntington disease brain. J. Neuropathol. Exp. Neurol. 60 (2001) 161-172
54. Schiffmann S.N., Jacobs O., and Vanderhaeghen J.J. Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. J. Neurochem. 57 (1991) 1062-1067
55. Shen P.J., and Gundlach A.L. Prolonged induction of neuronal NOS expression and activity following cortical spreading depression (SD): implications for SD- and NO-mediated neuroprotection. Exp. Neurol. 160 (1999) 317-332
56. Stack E.C., Smith K.M., Ryu H., Cormier K., Chen M., Hagerty S.W., Del Signore S.J., Cudkowicz M.E., Friedlander R.M., and Ferrante R.J. Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice. Biochim. Biophys. Acta 1762 (2006) 373-380
57. Streit W.J., and Kreutzberg G.W. Lectin binding by resting and reactive microglia. J Neurocytol. 16 (1987) 249-260
58. Tabrizi S.J., Cleeter M.W., Xuereb J., Taanman J.W., Cooper J.M., and Schapira A.H. Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Ann. Neurol. 45 (1999) 25-32
59. Tarditi A., Camurri A., Varani K., Borea P.A., Woodman B., Bates G., Cattaneo E., and Abbracchio M.P. Early and transient alteration of adenosine A2A receptor signaling in a mouse model of Huntington disease. Neurobiol. Dis. 23 (2006) 44-53
60. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72 (1993) 971-983
61. Thomas E., and Pearse A.G. The solitary active cells. histochemical demonstration of damage-resistant nerve cells with a TPN-diaphorase reaction. Acta Neuropathol. 3 (1964) 238-249
62. Turmaine M., Raza A., Mahal A., Mangiarini L., Bates G.P., and Davies S.W. Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. Proc. Natl. Acad. Sci. U. S. A 97 (2000) 8093-8097
63. Uemura Y., Kowall N.W., and Beal M.F. Selective sparing of NADPH-diaphorase-somatostatin-neuropeptide Y neurons in ischemic gerbil striatum. Ann. Neurol. 27 (1990) 620-625
64. Vannucchi M.G., Bizzoco E., Corsani L., Gianfriddo M., Pedata F., and Faussone-Pellegrini M.S. Relationships between neurons expressing neuronal nitric oxide synthase, degree of microglia activation and animal survival. A study in the rat cortex after transient ischemia. Brain Res. 1132 (2007) 218-227
65. Vannucchi M.G., Corsani L., Gianfriddo M., Pedata F., and Faussone-Pellegrini M.S. Expression of neuronal and inducible nitric oxide synthase in neuronal and glial cells after transient occlusion of the middle cerebral artery. Neuroscience 136 (2005) 1015-1026
66. Varani K., Rigamonti D., Sipione S., Camurri A., Borea P.A., Cattabeni F., Abbracchio M.P., and Cattaneo E. Aberrant amplification of A(2A) receptor signaling in striatal cells expressing mutant huntingtin. FASEB J. 15 (2001) 1245-1247
67. Varani K., Abbracchio M.P., Cannella M., Cislaghi G., Giallonardo P., Mariotti C., Cattabriga E., Cattabeni F., Borea P.A., Squitieri F., and Cattaneo E. Aberrant A2A receptor function in peripheral blood cells in Huntington's disease. FASEB J 17 (2003) 2148-2150
68. Wiesinger H. Arginine metabolism and the synthesis of nitric oxide in the nervous system. Prog. Neurobiol. 64 (2001) 365-391
69. Wu W., Liuzzi F.J., Schinco F.P., Depto A.S., Li Y., Mong J.A., Dawson T.M., and Snyder S.H. Neuronal nitric oxide synthase is induced in spinal cord neurones by traumatic injury. Neuroscience 61 (1994) 719-726
70. Wu W., Li Y., and Schinco F.P. Expression of c-jun and neuronal nitric oxide synthase in rat spinal motoneurons following axonal injury. Neurosci. Lett. 179 (1994) 157-161
71. Xiong H., Yamada K., Han D., Nabeshima T., Enikolopov G., Carnahan J., and Nawa H. Mutual regulation between the intercellular messengers nitric oxide and brain-derived neurotrophic factor in rodent neocortical neurons. Eur. J Neurosci. 11 (1999) 1567-1576
72. Zhang Z.G., Chopp M., Zaloga C., Pollock J.S., and Forstermann U. Cerebral endothelial nitric oxide synthase expression after focal cerebral ischemia in rats. Stroke 24 (1993) 2016-2021
73. Zeron M.M., Hansson O., Chen N., Wellington C.L., Leavitt B.R., Brundin P., Hayden M.R., and Raymond L.A. Increased sensitivity to N-methyl-d-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 33 (2002) 849-860
74. Zuccato C., Ciammola A., Rigamonti D., Leavitt B.R., Goffredo D., Conti L., MacDonald M.E., Friedlander R.M., Silani V., Hayden M.R., Timmusk T., Sipione S., and Cattaneo E. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 293 (2001) 493-498
75. Zucker B., Luthi-Carter R., Kama J.A., Dunah A.W., Stern E.A., Fox J.H., Standaert D.G., Young A.B., and Augood S.J. Transcriptional dysregulation in striatal projection- and interneurons in a mouse model of Huntington's disease: neuronal selectivity and potential neuroprotective role of HAP1. Hum. Mol Genet. 14 (2005) 179-189